Guides / weight-loss medication (GLP-1) / Cigna

How to Appeal a Weight-Loss Medication (GLP-1) Denial from Cigna

Denied for Zepbound, Wegovy, Ozempic, or Mounjaro? Step-therapy and "not medically necessary" denials are among the most overturnable — if you make the right argument.

Your deadline: most plans allow 180 days from the date on your denial letter to file an internal appeal — more time than most people think. Check the date on your letter.

Why weight-loss medication (GLP-1) claims get denied

Before appealing, check your plan’s prescription drug list. If weight-loss medications are excluded (not covered under any circumstances) rather than denied, a medical-necessity appeal cannot win — that is a benefit-design issue, not a coverage decision. Our free check tells you which one you’re facing before you spend anything.

The argument that wins

Evidence to gather

Appealing with Cigna

Cigna appeals are typically submitted through the myCigna portal or by mail to the address on your Explanation of Benefits. The standard internal appeal window is generally 180 days, with expedited review for urgent needs.

Whatever the channel, the argument is what wins — and that is the same regardless of insurer. Use the grounds above, attach the evidence, and file before your deadline.

Want this done for you?

Run a free case check — we read your denial, tell you if it’s appealable, and only charge ($149 flat) if it is. Expert-reviewed appeal in 2 business days.

Check my denial — free

Frequently asked questions

Can I appeal if my plan excludes weight-loss drugs entirely?

Usually not on medical-necessity grounds — a blanket exclusion is a benefit-design choice, not a coverage denial. Check your plan’s drug list first. Our free case check confirms this before you pay anything.

What if I haven’t tried the preferred drug?

You can request a step-therapy exception instead of completing the trial, if there is a clinical reason the preferred drug is inappropriate for you (a contraindication, a documented intolerance, or an FDA-indication mismatch).